Skip to main content

Table 2 Linear regression model showing clinicopathological factors that are independently associated with RANK and RANKL expression

From: RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy

 

Independent association with increasing RANKL expression ( P value)

Independent association with increasing RANK expression ( P value)

Diagnosis during pregnancy (yes vs. no)

<0.001

0.67

Tumor size (≤2 cm vs. >2 cm)

0.23

0.87

Nodal involvement (negative vs. positive)

0.15

0.19

Histological grade (I vs. II vs. III)

0.09

0.7

Breast cancer subtypes (luminal A vs. luminal B vs. HER2 vs. triple negative)

0.75

<0.001

Increasing progesterone receptor expression by IHC (continuous variable)

<0.001

0.17

Neoadjuvant chemotherapy (yes vs. no)

0.69

<0.001

  1. HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; RANK, receptor activator for nuclear factor κB; RANKL, receptor activator for nuclear factor κB ligand.